Communist Chinese Vaccines Infiltrate the United States

Communist Chinese Vaccines Infiltrate the United States

“The Chinese vaccine industry is developing rapidly due to an emerging and large market for current and new vaccines, a large potential for local vaccine manufacturing both in the public and private domain…”

Human Vaccines, China’s Emerging Vaccine Industry, July 2010, Vol. 6, Issue 7, https://pubmed.ncbi.nlm.nih.gov/20523120/

“China ranks second among countries that export drugs and biologics to the United States.”

United States Food and Drug Administration, Global Operations – China Office, January 28, 2020, https://www.fda.gov/about-fda/office-global-operations/china-office

“Chinese companies now account for more than 50% of the global active pharmaceutical ingredient (API) market. It has more than 500 companies registered to sell in the U.S. and 10 times that many serving its own market. But many of those continue to struggle to meet international standards.”

Fierce Pharma, China’s Drug Exports to the U.S. Rise but Companies Struggle With Quality, August 30, 2016, https://www.fiercepharma.com/manufacturing/china-drug-exports-to-u-s-rise-but-companies-struggle-quality

Since the inception of the 1986 National Vaccine Injury Compensation Program, the pharmaceutical industry started to offshore the manufacturing of vaccines. It did so to meet the growing demand in producing hundreds of millions of doses each year for the United States vaccination schedule that had quadrupled in size and scope. First, the vaccine makers harvested active pharmaceutical ingredients from Asia (primarily Communist China); then outsourced research and development. Over the past decade, the world’s top five vaccine manufacturers built plants in Communist China.

United States Food and Drug Administration, Exploring the Growing U.S. Reliance on China’s Biotech and Pharmaceutical Products, July 31, 2019, https://www.fda.gov/news-events/congressional-testimony/exploring-growing-us-reliance-chinas-biotech-and-pharmaceutical-products-07312019

Office of the United States (U.S.) Trade Representative, “Notice of Determination and Request for Public Comment Concerning Proposed Determination of Action Pursuant to Section 301: China’s Acts, Policies, and Practices,” (Docket No. USTR-2018-0005) (2018). https://ustr.gov/sites/default/files/files/Press/Releases/301FRN.pdf

United States Food and Drug Administration, Vaccines Licensed for Use In the United States, April 24, 2020, https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states

United States Food and Drug Administration, Importing CBER-Regulated Products Into the United States, https://www.fda.gov/vaccines-blood-biologics/exporting-cber-regulated-products/importing-cber-regulated-products-united-states

United States Food and Drug Administration, FDA Product Codes For Importing CBER-Regulated Products, October 10, 2018, https://www.fda.gov/vaccines-blood-biologics/exporting-cber-regulated-products/importing-cber-regulated-products-united-states

Leave a Reply

Your email address will not be published.